AzTrials
AzTrials

High Risk Abdominal WoundsPhase 4NCT02137447

Use of Negative Pressure Wound Therapy in High Risk Surgical Closed Incisions

A Phase 4 study testing Negative Pressure treatment in people with High Risk Abdominal Wounds, run by Massachusetts General Hospital at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to investigate the use of Negative Pressure Wound Therapy in high risk surgical wounds to evaluate the rate of surgical site infections (SSIs). Hypothesis: Historically, the average rates of infective complications in surgical wounds types are 7.7% in clean wounds, 15% for contaminated and… Read more about this study

Who is it for?
Ages 18 to 95 years
Conditions the study is for
High Risk Abdominal Wounds
What is being tested?
Negative Pressure treatment
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteUnited States
Study dates
May 2014to Sep 2016
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 95 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All five of the following criteria must be present for enrollment into the study:
  • Signed written informed consent must be provided by the patient or by patient's legally acceptable representative, if patient unable to consent.
  • Age > 18 years
  • Abdominal operation entering the peritoneal cavity under general anesthesia for colostomy or ileostomy reversal or enterocutaneous fistula excision
  • Clean - contaminated OR contaminated OR dirty wound (as defined by Wound Infection Surveillance) OR use of skin flaps for skin closure.
  • Complete closure of the surgical wound including the skin.

Who cannot join

  • 1) Known allergic reaction at the wound dressing parts of the Prevena ™ Incision Management System.
  • (Included but not limited to: sensitivity to silver, allergic or hypersensitivity reaction to acrylic adhesives).
  • 2) Inability to close the abdominal wall at the index procedure. 3) Inability to close the skin at the index procedure. 4) Patients under 18 years old. 5) Pregnant women test

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Massachusetts General Hospital

    Boston, Massachusetts, 02114

Other trials in United States

About this study

Official title: A Prospective Observational Study of the Use of Negative Pressure Wound in High Risk Surgical Closed Incisions.

The purpose of this study is to investigate the use of Negative Pressure Wound Therapy in high risk surgical wounds to evaluate the rate of surgical site infections (SSIs).

Hypothesis:

Historically, the average rates of infective complications in surgical wounds types are 7.7% in clean wounds, 15% for contaminated and 35-40% for dirty wounds. The application of Prevena ™ Incision Management System (Kinetic Concepts Inc, San Antonio, TX) is expected to reduce these rates by 50%.

Read the detailed description

Wound infections continue to be a common and costly problem after surgery. Surgical site infections (SSIs) are the second most common type of health care - associated infections (HAI), occurring in 2% to 5% of patients undergoing surgery in the United States. This percentage corresponds to approximately 300,000 to 500,000 surgical site infections (SSIs) estimated to occur each year.

Most SSIs that do not involve implants are diagnosed within 3 weeks post--operatively . SSIs lead to increased hospital stay, cost, and risk of death. The cost attributable to SSI range from $3,000 to $29,000 per SSI per patient depending on the type of operation; thus, the total annual cost approximately reaches the $10 billions. On other analyses documented nearly 1 million additional inpatient-days and $1.6 billion in excess costs , as well as up to twice the costs of a patient without SSI. Moreover, SSIs increase mortality risk by 2 to 11 fold 11, while the 77% of deaths in patients with SSI are attributed directly to the SSIs. Several organizations have put forth guidelines for definition and recommendations to decrease their incidence. Attempts have been made to stratify patients into various categories on the basis of the type of surgical procedure and risk factors the patients have, including diabetes, malnutrition, and hypoxemia. These systems have been used to develop criteria for the prevention of wound infection.

Appropriate timing and dosing of antibiotics, type of skin preparation, temperature of the patient in the operating room, blood oxygen level of the patient during surgery, and management of blood glucose levels all have been standardized in an attempt to decrease wound infection rates . In addition, debridement of all tissue that may contribute to wound infection, particularly ischemic skin and subcutaneous tissue, is standard surgical procedure. Standardization has led to a small decrease in incidence but has not led to a significant reduction in the overall rate. One reason for this is the multifactorial nature of SSI development. Factors regarding patients and pre-operative status, operative procedures and intra-operative events, as well as postoperative course, all need to be addressed, and there is not a complete understanding of their range and impact. What is known is that at the time of wound closure, one needs a minimal number of bacteria in the wound, and the wound itself must be reasonably well perfused and oxygenated. After surgery, wound perfusion and oxygenation are evaluated by clinical appearance. If the wound does not appear ischemic, it is assumed that perfusion and oxygenation are adequate. Unfortunately, this has never been quantified. Negative-pressure wound therapy (NPWT) has been used to speed the healing of open wounds.

How this occurs is not completely understood, but increased generation of granulation tissue at the margins of the open wound implies increased generation of blood vessels and substances needed to promote wound healing.

The theory of negative pressure is the stimulation of wound healing on the basis of improved perfusion to the wound. This has been seen in open wounds and has recently been applied to closed surgical wounds thought to be at high risk for infection. Negative-pressure wound therapy was also applied to closed wounds in an attempt to improve wound perfusion and oxygenation, which in theory would eliminate these two variables from the wound infection equation.

Techniques - Procedures Complete closure of the abdominal wall and skin follows the completion of the index surgical procedure. Closed suction drains may be used at the time of skin closure in any patient who requires skin flap elevation to attain skin closure. Skin closure will be accomplished with dermal sutures and / or staples. Wound coverage will be done with the NPWT Prevena ™ Incision Management System (Kinetic Concepts Inc, San Antonio, TX). The application of the NPWT will be done as per manufacturer's instructions of use. The application of continuous negative pressure will be applied at 125 mm Hg.Antibiotics will be given to all patients. The post-operative use of antibiotics in the clear contaminated and contaminated cases will be 24-hour of prophylactic administration. The post-operative use of antibiotics for the dirty (infected) cases will be of therapeutic administration, as clinically indicated. In infected patients, cultures will be taken at the time of the index procedure, and the antibiotic treatment will be targeted to the culture results. Wounds will be assessed every 48 hours by dressing changes, and also at the time of final dressing removal and at 2 and 4 weeks after surgery. The dressing removal will take place at discharge OR at 5 - 7 post-operative days OR if clinically indicated, whichever comes first. Post-discharge follow-up The patients will be followed-up per routine at the surgical clinic. At 2 and 4 weeks after the date of the operation a formal evaluation will take place. Both evaluations must be in person at the surgical clinic.

Being tested
Negative Pressure treatment
Keywords
Prevena, faster healing time, surgical site infection
Medical subject headings
Surgical Wound Infection

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Negative Pressure treatmentDevice

Study groups in NCT02137447
Study groupRoleWhat they receive
Negative Pressure Wound TherapyExperimentalAfter the completion of the operation, incisional skin closure was performed using sutures or staples and the wound was then covered with the Negative Pressure Wound therapy Prevena Incision Management System (Kinetic Concepts Inc) as per the manufacturer's instructions of use. Continuous negative pressure was applied at 125 mm Hg. For inpatients, wounds were assessed every 48 hours by inspection and palpation. The dressing was not routinely removed, but the surrounding skin was assessed for cellulitis. The NPWT dressing was removed between post-operative day 5 and 7
Receives: Device: Negative Pressure treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Surgical Site Infections Within 1 Month (4 Weeks ) From Index Operation

    Incidence of SSIs within 1 month (4 weeks) from the index operation. SSI is defined by the Centers for Disease Control and Prevention's National Healthcare Surveillance Network

    Measured: 30 days

Secondary outcomes (1)
  1. Composite Secondary Outcomes of Non-infectious Abdominal Wound Complications, Damage to the Skin Caused by the Dressing, Need to End the Treatment Prior to Discharge or Prior to 5-7 Post-operative Days, and Need for Reapplication of the System.

    Secondary (composite) outcomes:

    1. other non infectious abdominal wound complications,
    2. damage to the skin caused by the dressing
    3. need to end the treatment prior the discharge OR prior to 5 -7 post- operative days.
    4. need for re-application of the system for any reason

    Measured: 4 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 May 2014 (estimated)
  2. Study startMay 2014
  3. Primary completionSep 2016
  4. Study completionSep 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02137447
Sponsor's protocol ID
2013P002484
Status last verified
Mar 2017
First submitted
8 May 2014
Last updated
18 Apr 2017
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Negative Pressure treatment in people with High Risk Abdominal Wounds, run by Massachusetts General Hospital at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 20 Feb 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Surgical Site Infections Within 1 Month (4 Weeks ) From Index Operation (time frame: 30 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Apr 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in